Brief Title
Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM
Official Title
Phase IIA Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid With or Without Aspirin, for HIV-associated Tuberculous Meningitis
Brief Summary
LASER-TBM is a parallel group, randomized, multi-arm phase IIa trial evaluating the safety of
increased dose rifampicin (RIF) plus linezolid (LZD), with or without aspirin (ASA), for the
treatment of HIV-infected adults with tuberculous meningitis (TBM). The study will recruit
100 HIV-infected adults with TBM across four sites in South Africa.
The primary endpoint is the occurrence of solicited treatment-related adverse events.
Secondary endpoints include death and disability (including neurocognitive impairment),
radiological outcomes, and the occurrence of immune reconstitution inflammatory syndrome
(IRIS).
A nested pharmacokinetic (PK) substudy aims to:
1. Describe the plasma and cerebrospinal fluid (CSF) PK of LZD and high dose RIF.
2. Evaluate the relationship between drug exposures, toxicity and efficacy.
3. Compare exposures between intravenous and oral RIF administration.
4. Investigate the impact of high dose RIF on LZD and dolutegravir (DTG).
Detailed Description
HIV-1 infected adults with newly-diagnosed TBM (n = 100) will be recruited from four
public-sector hospitals in Cape Town and Port Elizebeth, South Africa. Participants will be
randomised across two experimental (n = 30 each) and one standard of care (n = 40) arms.
Treatment will be provided in all arms for 56 days, after which participants will be referred
back to public sector facilities to complete standard therapy for HIV-associated TBM.
The primary objective of the study is to investigate the safety of enhanced antimicrobial
therapy including increased dose RIF and LZD with or without adjunctive aspirin added to
standard therapy for TBM in HIV-1 infected adults.
Secondary objectives are;
1. To determine cerebrospinal fluid M.tb culture positivity and Gene Xpert® Ultra
positivity at baseline and at 3 and 28 days post treatment by allocation.
2. To evaluate the effect of aspirin and enhanced tuberculosis treatment on the incidence
of immune reconstitution syndrome in participants starting antiretroviral therapy.
3. To evaluate the effect of high dose rifampicin and linezolid, with and without aspirin
on the transcriptional signature derived from whole blood and cerebrospinal fluid RNA
sequencing, as well as the metabolomic and proteomic profiles, in tuberculous
meningitis.
4. To evaluate the effect of high dose rifampicin and linezolid with and without aspirin on
central nervous system imaging in conjunction with clinical, immunological and
transcriptional profiling.
5. To store biological samples for future analysis of potential biomarkers of treatment
efficacy and/or novel diagnostic assays.
6. To determine i) whether host genotype, including LTA4H genotype, influences therapeutic
effect of aspirin in HIV-TBM and ii) the pharmacogenetic influence on rifampicin and
linezolid exposures and toxicity.
All participants will receive antitubercular chemotherapy and corticosteroids as standard of
care as per national South African guidelines. Participants allocated to experimental arms 2
and 3 will receive additional rifampicin (total oral dose 35 mg/kg/day) plus oral linezolid
1200mg daily for the first 28 days, reduced to 600 mg daily for the next 28 days. Those
randomized to experimental arm 3 will also receive oral aspirin 1000 mg daily.
All consenting LASER-TBM participants in experimental arms (n = 60) will undergo a second
randomisation to receive either oral (35mg/kg) or IV (20mg/kg) rifampicin at the time of
study entry. This sub-study is powered to demonstrate bioequivalence at day 3 of
administration, after which all participants will be continued on oral rifampicin dosed at
35mg/kg.
Trial participation will be for 180 days post-randomization: primary safety endpoints and
secondary efficacy endpoints will be evaluated at day 56; additional secondary endpoints will
be evaluated at day 180.
There are seven scheduled study visits. The first six of thee will occur within the first 56
days, with an additional structured interview at 6 months. All visits will involve a clinical
assessment including specified clinical outcome measures to assess functional and cognitive
disability. Phlebotomy will be performed at study visits within the first 56 days to monitor
for pre-specified parameters of drug safety (haematology, biochemistry) as well as to collect
blood for downstream transcriptomic, proteomic and metabolomic analysis. Lumbar puncture will
take place at day 3 and day 28. Cerebrospinal fluid will be analysed for Mycobacterium
tuberculosis culture and Gene Xpert® Ultra cycle threshold values. Cerebrospinal fluid (CSF)
will be stored for downstream transcriptomic, proteomic and metabolomic analysis. Baseline
and day 56 brain imaging will be performed in all study participants.
All enrolled participants will undergo sparse plasma PK sampling at the Day 28 and Day 56
visits.
Cerebrospinal fluid (CSF) will be collected from all participants for determination of
linezolid and rifampicin concentrations on Days 3 and 28. The timing of the Day 3 lumbar
puncture will be randomised to intervals of 1 - 3, 3 - 6, 6 - 10, and 24 hours after observed
antitubercular drug dosing in order to construct a concentration-time profile for the
population. A single sample will be collected at each time interval. A second lumbar puncture
will take place at the Day 28 visit, to coincide with the 4-hour plasma PK sample.
All participants (n=100) will be offered participation in the intensive sampling component of
the PK sub-study at the time of randomization to the main study. Intensive plasma sampling
will take place at the Day 3 study visit. Serial venous blood samples will be collected
through a peripheral intravenous catheter pre-dose, and at 0.5, 1, 2, 3, 6, 8 - 10, and 24
hours after witnessed drug intake and an overnight fast. Sparse sampling will be performed at
Day 3 for participants who decline intensive sampling or in whom this fails.
Study Phase
Phase 2
Study Type
Interventional
Primary Outcome
Number of participants in each arm who develop treatment related adverse events (AEs).
Secondary Outcome
Death and disability after 56 days on treatment.
Condition
Tuberculosis Meningitis
Intervention
Linezolid
Study Arms / Comparison Groups
Standard of care anti-tubercular therapy
Description: Standard of care anti-TB treatment. (10 mg/kg oral rifampicin, 5 mg/kg oral isoniazid, 15 mg/kg oral ethambutol and 25 mg/kg oral pyrazinamide daily for 2 months as fixed dose combination tablets (followed by 10 mg/kg oral rifampicin and 5 mg/kg isoniazid daily for 4-7 months in routine care after study completed)).
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
52
Start Date
June 12, 2019
Completion Date
March 31, 2021
Primary Completion Date
March 30, 2021
Eligibility Criteria
Inclusion Criteria:
- HIV-1 seropositivity by rapid test, confirmed by enzyme-linked immunosorbent assay
(regardless of Antiretroviral Therapy (ART) status);
- Age 18 years or older;
- Tuberculous meningitis defined as 'possible', 'probable' or 'definite' as per
published case definitions
Exclusion Criteria:
- Rifampicin-resistant M. tb detected in any microbiological specimen;
- History of allergy or hypersensitivity to H, E, R and Z, LZD or ASA;
- Received more than 5 days of antitubercular therapy in the 30 days prior to screening;
- Received a dose of ASA or any other NSAID within 2 weeks of screening;
- CSF unobtainable by lumbar puncture or another procedure;
- Evidence of bacterial or cryptococcal meningitis;
- Severe concurrent uncontrolled opportunistic infection including but not limited to
active cytomegalovirus-associated disease, Kaposi sarcoma, Pneumocystis jirovecii
pneumonia, HIV related or unrelated malignancy or gastrointestinal bleeding;
- Any other form of immunosuppressive therapy including antineoplastic and biologic
agents apart from corticosteroids;
- Is pregnant in the third trimester;
- Peripheral neuropathy scoring Grade 3 or above on Brief Peripheral Neuropathy Score
- Any disease or condition in which the use of the standard TB drugs or any of their
components is contraindicated, including but not limited to allergy to any TB drug or
their components;
- The presence of one or more of the following:
- Estimated glomerular filtration rate (eGFR) < 20ml/min/1.73m2 (using the
Cockcroft-Gault equation)
- International normalised ration (INR) > 1.4 and/or clinical evidence of liver
failure or decompensated cirrhosis
- Hemoglobin < 8.0 g/dL
- Platelets < 50 x109 /L
- Neutrophils < 0.5 x 109 cells/L;
- The patient has any disease or condition in which any of the medicinal products listed
in the section pertaining to prohibited medication is used and cannot be safely
stopped;
- The patient has a known or suspected, current or history of drug abuse, within the
past 2 years, that is, in the opinion of the investigators, sufficient to compromise
the safety or cooperation of the patient.
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Robert J Wilkinson, PhD, ,
Location Countries
South Africa
Location Countries
South Africa
Administrative Informations
NCT ID
NCT03927313
Organization ID
LASER-TBM
Responsible Party
Principal Investigator
Study Sponsor
University of Cape Town
Study Sponsor
Robert J Wilkinson, PhD, Principal Investigator, Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town
Verification Date
September 2021